Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Investing.com - H.C. Wainwright reiterated a Buy rating and $5.00 price target on Editas Medicine (NASDAQ:EDIT), currently trading at $2.52, following the company’s nomination of EDIT-401 as its lead in vivo program. According to InvestingPro data, analyst targets for the stock range from $1 to $6, with the company’s market capitalization standing at $226.6 million.
EDIT-401, a GalNAc-LNP delivered CRISPR candidate, edits the LDLR 3’-UTR to stabilize mRNA and drive ≥6-fold receptor up-regulation. Preclinical studies demonstrated approximately 90% mean LDL-C reductions across various models, compared to 40-60% with statins or PCSK9i.
Safety data appeared favorable, with only transient liver function test elevations that resolved within a week and no hematologic issues. The company noted an Icelandic family carrying a natural LDLR 3’-UTR deletion has extremely low LDL without adverse effects.
Editas expects to disclose one more in vivo target by the end of 2025, file Investigational New Drug and Clinical Trial Application submissions by mid-2026, and report first-in-human proof-of-concept data by the end of 2026. The company reports a cash runway extending into the second quarter of 2027.
H.C. Wainwright incorporated the Heterozygous Familial Hypercholesterolemia (HeFH) opportunity with a 15% probability of approval into its model while removing Sickle Cell Disease (SCD) and Transfusion-Dependent Beta-Thalassemia (TDT) programs.
In other recent news, Editas Medicine has seen several updates from analysts regarding its stock price targets. Wells Fargo increased its price target for Editas Medicine to $4.00 from $3.00, maintaining an Equal Weight rating, based on promising preclinical data for the company’s EDIT-401 treatment. This data showed a significant increase in LDLR protein in non-human primates, leading to a substantial reduction in LDL-C levels without adverse clinical observations. Additionally, H.C. Wainwright raised its price target to $5.00 from $3.00, maintaining a Buy rating, after Editas announced it expects to select its first in vivo lead candidate by September 2025. Baird also increased its price target to $6.00 from $4.00, maintaining an Outperform rating, following Editas Medicine’s second-quarter 2025 earnings and pipeline updates, which were in line with expectations. Meanwhile, NuCana plc has released its 2024 UK Annual Report and announced its Annual General Meeting for June 27, 2025. The report provides insights into NuCana’s financial performance and strategic initiatives over the past year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.